Preventing mucus plugs in COPD: a potential role for erdosteine
Open Access
- 27 August 2026
- journal article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 68 (2) , 2601274
Abstract
Extract To the Editor: Mucus plugging is an important component of clinical deterioration in COPD. Erdosteine, a muco-active agent used early in the evolution of COPD, reduces exacerbations and may slow plug development. https://bit.ly/4ePJlf9Keywords
This publication has 8 references indexed in Scilit:
- The pathobiology and treatment of mucus plugs in asthma and COPD: state of the artEuropean Respiratory Journal, 2026
- Effect of Treatment with Mucoactive Drugs on COPD Exacerbations During 5 years of Follow-up in the Czech Republic: A Real-World StudyLung, 2025
- Accelerated Lung Function Decline and Mucus–Microbe Evolution in Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2024
- Airway mucins promote immunopathology in virus-exacerbated chronic obstructive pulmonary diseaseJournal of Clinical Investigation, 2022
- Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow LimitationInternational Journal of Chronic Obstructive Pulmonary Disease, 2019
- Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteineRespiratory Research, 2019
- Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE studyEuropean Respiratory Journal, 2017
- Exacerbation frequency and course of COPDInternational Journal of Chronic Obstructive Pulmonary Disease, 2012